United States: FDA Releases Biosimilar Guidance For Industry

Last Updated: January 10 2017
Article by Jacob D. Moore

On December 29, 2016, the FDA issued guidance to assist applicants seeking FDA approval of a proposed biosimilar product under the Biologics Price Competition and Innovation Act of 2009 (BPCIA). To obtain such approval, an applicant must demonstrate that the proposed product is "biosimilar" to a reference biological product already approved by the FDA. The new biosimilar guidance provides information on how such a showing can be made.

Biosimilar By The Totality Of The Data And Information

Consistent with previous biosimilar guidance, the December 2016 guidance highlights the importance of a holistic evaluation of biosimilarity based on analytical data (e.g., structural and functional comparisons between the biological product and the reference product), animal studies, and clinical studies. According to the guidance, analytical data revealing differences between the proposed and reference products may not per se disqualify the proposed product from being approved as a biosimilar, but obtaining approval of such a product likely will require additional studies—e.g., animal or clinical studies—explaining or addressing those differences in a clinical context. On the other hand, the guidance indicates that if the proposed and reference products show a high level of analytic similarity (e.g., products with so-called "fingerprint-like analytical similarity"), approval may be obtained via a "more targeted and selective approach to conducting animal and/or clinical studies [to] resolve residual uncertainty and . . . support a demonstration of biosimilarity."

Complementing the FDA's emphasis on a holistic "totality of the data and information" approach, the guidance advocates adopting a step-wise approach to data collection. For example, the guidance proposes that analytical studies be conducted before animal or clinical trials are even designed. That way, the results of initial analytical experiments can illuminate the course of subsequent animal or clinical trials. Subsequent studies can be designed—with feedback from the FDA—to specifically address any differences/uncertainties observed in the earlier studies.

The "Critical" Role Of Clinical Pharmacology Studies

The guidance provides specific recommendations regarding the "critical" role of clinical pharmacology studies to a biosimilar evaluation. Particularly relevant are pharmacokinetic (PK) and pharmacodynamics (PD) data, which should provide exposure (e.g., C¬max, Ctrough ss and AUC data) and exposure-response (e.g., data showing the relationship between drug exposure and the pharmacological or toxicological effect) information for both the proposed and reference products.

While both PK and PD data are preferred by the FDA, the agency recognizes that the "complex molecular structure" of biological products may pose challenges in obtaining this data. For example, the guidance acknowledges that "conventional" bioanalytical methods for evaluating PK and PD might not be suitable. The guidance therefore points to the "particular importance" of specific bioanalytical methods, such as ligand binding assays, concentration and activity assays, and/or PD assays (e.g., using biomarkers as discussed below), that can be used to support a biosimilar application.

Collecting informative PD response data can be especially challenging in the context of demonstrating biosimilarity between proposed and reference biological products. With this in mind, the guidance stresses that a PD response can be evaluated by monitoring a biomarker or a panel of biomarkers that "effectively demonstrate the characteristics of the product's target effects." In assessing target biomarker(s) that might be useful for this purpose, the guidance highlights the importance of the following five characteristics:

  • The time of onset of change in the PD biomarker relative to dosing and its return to baseline with discontinuation of dosing
  • The dynamic range of the PD biomarker over the exposure range to the biological product
  • The sensitivity of the PD biomarker to differences between the proposed biosimilar product and the reference product
  • The relevance of the PD biomarker to the mechanism of action of the drug (to the extent that the mechanism of action is known for the reference product)
  • The analytical validity of the PD biomarker.

Conducting pharmacological experiments that account for the above characteristics will facilitate the FDA evaluation of whether the proposed product is sufficiently biosimilar to the reference product to support approval.

Communication With FDA Is Key

The guidance stresses the importance of maintaining an open dialogue with the FDA regarding a proposed clinical pharmacology development plan. Such communication will ensure that clinical trials are designed to resolve lingering uncertainty (and address FDA concerns) regarding biosimilarity. With this in mind, the guidance sets forth several "critical topics" that should be discussed with the FDA "in the early stages of the biosimilar product development plan." These topics include

  • study design
  • the reference product used in the studies
  • the study population,
  • dose selection,
  • route of administration
  • the PK measurements to be obtained
  • the PD measurements to be obtained
  • the time profile for PD measurements and
  • the appropriate statistical analysis to apply when evaluating the clinical data.

Biosimilar Applicants Should Welcome The Detailed Guidance

Applicants seeking a license for a biosimilar product likely will welcome the new guidance. Especially helpful may be the detailed recommendations regarding PK and PD experiments. Indeed, such recommendations set forth with greater clarity a path by which an applicant can obtain FDA approval for their biosimilar product.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.